Skip to content

DMAC

DiaMedica Therapeutics Inc.

NASDAQ · Healthcare · Biotechnology · US

$7.87
+3.96%
Ask drillr

Year over year

Reported trailing growth

Revenue
—
EBITDA
-24.3%
EBIT
-23.5%
EPS
-4.3%
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
+68.0%
EPS
-5.9%

Three-year CAGR

Revenue
—
EBITDA
-34.1%
EBIT
-28.9%
Net income
-34.0%
EPS
-16.7%
Free cash flow
-31.7%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026